8/30/2013

The European Commission and the FDA have granted orphan-drug status to ReNeuron's stem cell drug ReN003 as a treatment for retinitis pigmentosa. ReNeuron plans to apply next year to conduct a Phase I/II study in the U.S. and the U.K.

Full Story:
PharmaTimes (U.K.)

Related Summaries